Presence of tobramycin in kidneys and placentae of sprague-dawley rat fetuses and newborns following in utero exposure

The maternal-fetal transfer of tobramycin (TBM) was investigated in the rat by means of a microbiological assay, to assess the presence and amount in the kidneys and placentae of fetuses at gestational day (GD) 20, in the kidneys of newborns 6 and 1 I days after the end of treatment and in the kidne...

Full description

Saved in:
Bibliographic Details
Published in:Pharmacological research 1992-10, Vol.26 (3), p.277-284
Main Authors: Ferrini, A.M., Aureli, P., Ricciardit, C., Stazit, A.V., Macri`, C., Mantovanit, A.
Format: Article
Language:English
Subjects:
Animals
Animals, Newborn
Antibacterial agents
Antibiotics. Antiinfectious agents. Antiparasitic agents
Biological and medical sciences
Biological Assay
Female
Fetus - metabolism
kidney
Kidney - embryology
Kidney - metabolism
Male
Maternal-Fetal Exchange
Medical sciences
offspring
Pharmacology. Drug treatments
Placenta - metabolism
placental transfer
Pregnancy
Rats
Rats, Sprague-Dawley
tobramycin
Tobramycin - pharmacokinetics
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:The maternal-fetal transfer of tobramycin (TBM) was investigated in the rat by means of a microbiological assay, to assess the presence and amount in the kidneys and placentae of fetuses at gestational day (GD) 20, in the kidneys of newborns 6 and 1 I days after the end of treatment and in the kidneys of the dams. In the qualitative assay, pregnant rats were injected i.p. with 0, 30, 60 mg/kg b.w. of TBM on GD 10–19. A group of dams treated in parallel with 30 mg/kg b.w. was utilized for a microbiological semiquantitative assay. All litters contained some fetuses showing no detectable TBM accumulation in either kidney or in placentae: at 30 mg/kg/b.w. accumulation appeared more prevalent in placenta than in the kidneys of the corresponding fetuses, as confirmed also by the semiquantitative assay. Some newborns (about 6%) of both groups showed detectable renal TBM residues on the 6th and on the 11th day after the end of treatment. The frequency of newborns showing residues was not obviously related to the dose or the day of sampling, and the concentrations of TBM found were comparable to those observed in fetuses. It is possible that they represent a particularly sensitive subgroup.
ISSN:1043-6618
1096-1186
DOI:10.1016/1043-6618(92)90216-X